Insider at Zomedica (ZOMDF) adds 216,899 shares in open-market buys

Rhea-AI Filing Summary

Zomedica Corp. senior vice president of sales Klass Russell Kevin reported buying additional company stock in the open market. He purchased a total of 216,899 shares of common stock in three transactions at prices between $0.105 and $0.107 per share. Following these purchases, his directly held stake increased to 5,984,101 common shares.

Insider Trade Summary

Net Buyer: 216,899 shares ($22,797)

Net Buy 3 txns

Insider Klass Russell Kevin

Role null

Bought 216,899 shs ($23K)

Type	Security	Shares	Price	Value
Purchase	Common Stock, without par value	200,000	$0.105	$21K
Purchase	Common Stock, without par value	11,399	$0.107	$1K
Purchase	Common Stock, without par value	5,500	$0.105	$577.50

Holdings After Transaction: Common Stock, without par value — 5,984,101 shares (Direct, null)

Footnotes (1)

Key Figures

Open-market purchase 1: 5,500 shares at $0.105/share Open-market purchase 2: 11,399 shares at $0.107/share Open-market purchase 3: 200,000 shares at $0.105/share +4 more

7 metrics

Open-market purchase 1 5,500 shares at $0.105/share First common stock transaction, open-market purchase

Open-market purchase 2 11,399 shares at $0.107/share Second common stock transaction, open-market purchase

Open-market purchase 3 200,000 shares at $0.105/share Largest single common stock transaction, open-market purchase

Total shares purchased 216,899 shares Sum of three reported open-market purchases

Post-transaction holdings 5,984,101 shares Directly owned common shares after reported trades

Lowest purchase price $0.105/share Lowest per-share price among reported transactions

Highest purchase price $0.107/share Highest per-share price among reported transactions

Key Terms

open-market purchase, Common Stock, without par value, Form 4, transaction code "P", +1 more

5 terms

open-market purchase financial

"transaction_action": "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Common Stock, without par value financial

""security_title": "Common Stock, without par value""

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

transaction code "P" financial

""transaction_code": "P""

net-buy financial

""netBuySellDirection": "net-buy""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Klass Russell Kevin

(Last) (First) (Middle)

1101 TECHNOLOGY DRIVE.

STE 100.

(Street)

ANN ARBOR. MICHIGAN 48108

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Zomedica Corp. [ ZOMDF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Sr. Vice President, Sales

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, without par value	05/20/2026		P		200,000	A	$0.105	5,984,101	D
Common Stock, without par value	05/21/2026		P		11,399	A	$0.107	5,995,500	D
Common Stock, without par value	05/21/2026		P		5,500	A	$0.105	6,001,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/Kevin Klass	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider activity did Zomedica (ZOMDF) report in this Form 4?

Zomedica reported that senior vice president of sales Klass Russell Kevin bought company common stock. He made three open-market purchases, increasing his directly held stake and signaling a higher personal ownership position in Zomedica shares.

How many Zomedica (ZOMDF) shares did the insider purchase?

The insider purchased a total of 216,899 Zomedica common shares. This total comes from three separate open-market transactions reported in the Form 4 filing, each adding to his direct ownership position in the company’s stock.

At what prices did the Zomedica (ZOMDF) insider buy shares?

The reported purchases occurred at prices between $0.105 and $0.107 per share. One trade was at $0.105, another at $0.107, and a larger 200,000-share transaction was also executed at $0.105 per Zomedica common share.

How many Zomedica (ZOMDF) shares does the insider own after these trades?

After the reported purchases, the insider directly holds 5,984,101 Zomedica common shares. This post-transaction ownership figure reflects his increased stake following the three open-market buy transactions disclosed in the Form 4 filing.

What type of transactions were reported for Zomedica (ZOMDF) in this Form 4?

All reported transactions were open-market purchases of Zomedica common stock. Each trade is coded as a “P” transaction, indicating a purchase in the open market or a private transaction under SEC reporting rules.

Who is the insider involved in the Zomedica (ZOMDF) Form 4 filing?

The Form 4 identifies Klass Russell Kevin as the reporting person. He is described as Zomedica’s senior vice president of sales and holds the reported common stock directly in his own name after the transactions.